Hormesis and Endothelial Progenitor Cells

Dose Response. 2022 Feb 23;20(1):15593258211068625. doi: 10.1177/15593258211068625. eCollection 2022 Jan-Mar.ABSTRACTHormetic-biphasic dose response relationships are reported herein for human endothelial progenitor cells involving estradiol, nicotine, the anti-diabetic agent pioglitazone, resveratrol, and progesterone. In general, these studies demonstrate the capacity of these agents to enhance EPC proliferation and angiogenesis functional applications, having a focus on repairing endothelial tissue damage due to acute injury (e.g., stroke), as well as damage from chronic conditions (e.g., atherosclerosis) and normal aging processes.PMID:35221821 | PMC:PMC8874175 | DOI:10.1177/15593258211068625

Source: Dose Response - February 28, 2022 Category: Drugs & Pharmacology Authors: Edward J Calabrese Source Type: research